Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study
Authors' conclusion
SGLT-2i was associated with significant reductions in depression and mortality risks, highlighting its potential advantages for type 2 diabetes management. 1 Background.
Study context
- Population
- Patients with T2D receiving monotherapy with metformin, GLP-1 RA, DPP-4i or SGLT-2i (TriNetX)
- Participants
- 359,787 patients
- Exposure
- Metformin vs GLP-1 RA vs DPP-4i vs SGLT2i monotherapy
- Outcome
- Incident depression and all-cause mortality
- Follow-up
- 1-, 3- and 5-year follow-up
Methodological detailspropensity-score matched, TriNetX
- Propensity-score matched
- TriNetX
Main finding
As reported in the abstract
1, 3 and 5 years
- GLP-1 RA vs Metformin · depression
- HR 1.54-1.84
- GLP-1 RA vs Metformin · all-cause mortality, 1 year
- HR 1.19
- GLP-1 RA vs Metformin · all-cause mortality, 3 years; not observed at 5 years
- HR 1.21
- GLP-1 RA vs SGLT-2i · depression
- HR 1.33-1.59
- GLP-1 RA vs SGLT-2i · all-cause mortality
- HR 1.24-1.35
- SGLT-2i vs DPP-4i · depression
- HR 0.62-0.70
- SGLT-2i vs DPP-4i · all-cause mortality
- HR 0.54-0.65
- DPP-4i vs Metformin · depression
- HR 1.53-1.74
- DPP-4i vs Metformin · all-cause mortality
- HR 1.56-1.57
Observational data: associations, not effects.
Original publication
Association of antidiabetic medications with depression risk and All-Cause mortality in type 2 Diabetes: A TriNetX-Based cohort study. Diabetes Res Clin Pract. Published 9 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →